The global biopharmaceutical third-party logistics market was valued at USD 152.0 billion in 2025 and is projected to increase from USD 161.4 billion in 2026 to USD 258.4 billion by 2033, registering a CAGR of 6.9% from 2026 to 2033. North America dominated the market in 2025, accounting for a revenue share of 41.7%.

Market growth is primarily driven by the expanding commercialization of biologics and biosimilars, increasing demand for temperature-controlled and Good Distribution Practice (GDP)-compliant logistics infrastructure, and rising outsourcing of pharmaceutical supply chain operations. Additionally, the growth of clinical trials and advanced therapies, including cell and gene therapies, and the adoption of digital supply chain technologies are strengthening demand for specialized logistics services.

Biopharmaceutical Third-Party Logistics Market Overview

According to Grand View Research, the global biopharmaceutical third-party logistics market is expected to experience steady growth through 2033. The increasing complexity of pharmaceutical distribution and stringent product-handling requirements are encouraging pharmaceutical and biotechnology companies to partner with specialized third-party logistics (3PL) providers. These providers offer integrated solutions covering transportation, warehousing, storage, packaging, inventory management, and cold chain distribution.

Go Deeper! Ask Prism AI

about the Global biopharmaceutical third-party logistics market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.

Key Market Trends & Insights

Biopharmaceutical Third-Party Logistics Market Size & Forecast

Market Indicator

Value

Market size in 2025

USD 152.0 billion

Estimated market size in 2026

USD 161.4 billion

Projected market size in 2033

USD 258.4 billion

CAGR (2026–2033)

6.9%

Download a free sample report or claim your copy of this full market intelligence report

Market Growth Drivers, Opportunities & Challenges

Expanding Biologics and Advanced Therapies Drives Demand for Specialized Logistics

The rapid expansion of biologics, biosimilars, and advanced therapies is a major factor driving the growth of the biopharmaceutical third-party logistics market. Unlike conventional pharmaceutical products, biologics require specialized transportation, temperature-controlled storage, validated packaging, and continuous environmental monitoring to maintain product stability, efficacy, and regulatory compliance.

The growing commercialization of monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies is increasing the need for specialized logistics providers with GDP-compliant infrastructure and established global distribution networks. These requirements are encouraging logistics companies to expand their cold chain capabilities, invest in specialized storage facilities, and develop advanced monitoring solutions to support the safe transportation of sensitive pharmaceutical products.

Increasing Pharmaceutical Supply Chain Outsourcing Supports Market Expansion

The growing outsourcing of pharmaceutical supply chain operations is another significant factor supporting market expansion. Pharmaceutical and biotechnology companies are increasingly partnering with specialized third-party logistics providers to improve distribution efficiency, strengthen regulatory compliance, reduce operational costs, and enhance supply chain resilience across international markets.

Managing biopharmaceutical supply chains requires specialized expertise in cold chain management, customs clearance, serialization, inventory control, and last-mile delivery. Outsourcing these activities enables manufacturers to access established logistics networks and specialized infrastructure without making substantial investments in internal distribution capabilities.

Strategic investments and acquisitions across the logistics industry further highlight the growing importance of specialized pharmaceutical logistics services. For instance, in March 2025, DHL announced the acquisition of specialty pharmaceutical logistics provider CryoPDP to strengthen its capabilities in clinical trial logistics, biopharmaceutical distribution, and cell and gene therapy transportation. The acquisition also supports the expansion of DHL's integrated healthcare logistics portfolio and specialized cold chain network.

High Infrastructure Costs and Regulatory Complexity Remain Key Challenges

Despite favorable growth prospects, the biopharmaceutical third-party logistics market faces challenges associated with high capital investment requirements and stringent regulatory compliance. Establishing temperature-controlled warehouses, specialized transportation networks, validated packaging systems, and continuous monitoring infrastructure requires substantial financial resources.

Furthermore, transporting sensitive biopharmaceutical products across international markets involves complex regulatory procedures, customs requirements, product traceability standards, and temperature management protocols. Any deviation from prescribed storage or transportation conditions can compromise product quality and increase operational risks. These factors can create barriers to entry for smaller logistics providers and increase operating costs across the industry.

Digitalization and Cold Chain Investments Create Growth Opportunities

The increasing commercialization of advanced therapies, expansion of biologics development pipelines, and growing adoption of digital supply chain technologies are expected to create significant opportunities for market participants.

Technologies such as real-time shipment tracking, Internet of Things (IoT)-enabled temperature monitoring, data analytics, and automated inventory management are improving supply chain visibility and operational efficiency. These solutions enable logistics providers to monitor product conditions, identify potential disruptions, and maintain compliance throughout the distribution process.

Additionally, continued investments in GDP-compliant cold chain infrastructure and specialized transportation capabilities are expected to strengthen the industry's ability to handle increasingly complex pharmaceutical products. As pharmaceutical manufacturers continue to outsource specialized logistics operations, providers offering secure, compliant, and globally integrated distribution solutions are positioned to benefit from long-term market growth.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Regional Highlights

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Key Biopharmaceutical Third-Party Logistics Companies

The global biopharmaceutical third-party logistics market includes established logistics companies and specialized pharmaceutical supply chain providers offering transportation, warehousing, cold chain management, and distribution services.

The following companies have been profiled in the market study:

Explore our dedicated business services:U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today

The Influence of Biosimilar Adoption on the Biopharmaceutical Third-Party Logistics Market

The global biopharmaceutical third-party logistics market was valued at USD 152.0 billion in 2025 and is projected to increase from USD 161.4 billion in 2026 to